Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07139548
PHASE3
A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes
Sponsor: Guangdong Raynovent Biotech Co., Ltd
View on ClinicalTrials.gov
Summary
The reason for this study is to compare the effect of the study drug RAY1225 to semaglutide on blood sugar levels in participants with type 2 diabetes.
Official title: A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Patients With Type 2 Diabetes
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
600
Start Date
2025-08-31
Completion Date
2026-12-31
Last Updated
2025-08-24
Healthy Volunteers
No
Conditions
Interventions
DRUG
RAY1225
Administered SC
DRUG
Semaglutide
Administered SC
Locations (1)
Peking University People's Hospital
Beijing, Heibei, China